PDCD1 and neoplasm: Furthermore, immune checkpoint inhibitors, particularly programmed death-1 (PD-1) inhibitors, have shown synergistic antitumor effects when combined with TKIs and HAIC in advanced HCC, presumably by modulating the immunosuppressive tumor microenvironment and extending patient survival (16, 17).